Presage's Medical Advisory Panel members provide the company with insights on evolving treatment paradigms and novel therapeutic approaches.
Medical Advisory Panel
Keith T. Flaherty, M.D.
Dr. Flaherty joins us from Massachusetts General Hospital where he serves as Director of Developmental Therapeutics in the Cancer Center. He is also an Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research is focused on understanding and developing targeted therapies for cancer with a particular focus on disrupting signal transduction pathways in melanoma. He has more than 200 publications and lends expertise as a principal investigator or co-investigator on several Phase I, II, and III clinical trials. He is known for his pivotal role in developing vemurafenib, an FDA approved drug for melanoma. Dr. Flaherty obtained an M.D. degree from Johns Hopkins School of Medicine.
Ghassan Abou-Alfa, M.D.
Dr. Abou-Alfa joins us from Memorial Sloan Kettering Cancer Center where he focuses on cancers that originate in the liver (hepatocellular cancer and biliary tree). He is also an Associate Professor of Medicine at Weill Cornell Medical College and the current chair of the National Cancer Institute (NCI) hepatobiliary Task Force. Dr. Abou-Alfa is a renowned authority on primary liver cancer (hepatocellular cancer). His research focus is on developing small-molecule cancer therapies for primary liver cancer and biliary cancers. Dr. Abou-Alfa has played a pivotal role on global and national clinical trials including work on sorefenib, a small-molecule cancer therapy that was approved by the FDA in 2007. Dr. Abou-Alfa obtained an M.D. degree from American University in Beirut and completed his post-doctoral training at Yale University.
Carlos L. Arteaga, M.D.
Dr. Arteaga joins us from Vanderbilt-Ingram Cancer Center of Vanderbilt University where he serves as the Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program. He also serves as the Donna S. Hall Chair in Breast Cancer Research and Professor of Medicine and Cancer Biology. Dr. Arteaga also directs the Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) and participates in several investigator-initiated clinical trials and program projects. With over 300 publications and 25 years of experience, Dr. Arteaga has a wealth of experience in oncogene signaling in breast cancer cells, mechanisms of drug resistance, and translational breast cancer research. Dr. Arteaga obtained his M.D. degree from the Facultad de Ciencias Médicas, Universidad de Guayaquil in Ecuador.
Manuel Hidalgo, M.D., Ph.D.
Dr. Hidalgo joins us from the Centro Nacional de Investigaciones Oncológicas (CNIO; Spanish National Cancer Research Center) in Spain. He joined CNIO in 2009 to lead the GI Cancer Clinical Research Unit and was later a founding member of the pancreatic cancer research team at CNIO. Currently, Dr. Hidalog directs research at Beth Israel Deaconess Medical Center (BIDMC). He has extensive drug development experience having worked with over 30 novel anticancer agents, two of which were recently approved by the FDA. Dr. Hidalgo has more than 180 publications with a current focus on novel therapeutics in pancreatic cancer. Dr. Hidalgo obtained an M.D. degree from the Universidad de Navarra, Pamplona and a Ph.D. from the Universidad Autonoma de Madrid.
Ian E. Krop, M.D., Ph.D.
Dr. Krop joins us from the Dana-Farber Cancer Institute/Harvard Cancer Center. He serves as Chair of Breast Medical Oncology and the Director of Breast Cancer Clinical Research at Dana-Farber. He is also an Assistant Professor of Medicine at Harvard Medical School. Dr. Krop is focused on developing novel targeted breast cancer therapies and working to understand resistance to HER2-targeted therapies. He has led both early and late-stage clinical trials for several HER2-directed agents. Dr. Krop obtained an M.D. degree and a Ph.D. from Johns Hopkins University.
Robert G. Maki, M.D., Ph.D.
Dr. Maki joins us from the Center for New Cancer Therapies at Northwell Health and Cold Spring Harbor Laboratory. He serves as the Director of Translational Oncology at SARC, a Professor of Medicine, Pediatrics, and Orthopedics, and the Steven Ravitch Chair in Pediatric Hematology-Oncology. He has worked in sarcoma for approximately 30 years publishing over 100 articles on treatment of sarcoma and basic science research. His current focus is translational sarcoma research and treatment of soft tissue and bone sarcomas. Dr. Maki obtained an M.D. degree and a Ph.D. from Cornell University.
Eileen M. O’Reilly, M.D.
Dr. O’Reilly joins us from Memorial Sloan Kettering Cancer Center where she works as a medical oncologist and Faculty Member. She is also a Professor of Medicine at Weill Cornell Medical College and co-chair for the gastrointestinal group of the Alliance Co-operative group. Dr. O’Reilly is an authority in pancreatic cancer research and treatment with additional expertise in esophageal, gastric, hepatobiliary, and colorectal cancers. She has served as the principal investigator on numerous pancreatic cancer clinical trials. Dr. O’Reilly obtained an M.D. degree from the University of Dublin Trinity College School of Medicine in Dublin, Ireland.
Mark Pegram, M.D.
Dr. Pegram joins us from Stanford University. He serves as the Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, Co-Director of Stanford’s Molecular Therapeutics Program, and Associate Director for Clinical Research, Stanford Cancer Institute. He has a history of success in bench-to-bedside translational research with his pivotal role in bringing Herceptin to patients diagnosed with HER2-positive breast cancer. Dr. Pegram is currently focused on breast cancer molecular therapeutics. He obtained an M.D. degree from the University of North Carolina.
Anas Younes, M.D.
Dr. Younes joins us from Memorial Sloan Kettering Cancer Center where he serves as Chief of Lymphoma Service. He has over 20 years of experience in the areas of Hodgkin and non-Hodgkin lymphoma and has served as a principal investigator on more than 60 clinical trials. His current work is focused on developing novel targeted therapies for the treatment of Hodgkin and non-Hodgkin lymphoma. Dr. Younes obtained an M.D. degree from the University of Damascus School of Medicine.
Andrew X. Zhu, M.D., Ph.D.
Dr. Zhu joins us from Massachusetts General Hospital where he serves as the Director of Liver Cancer Research. He also works as an Associate Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through Phase I, II, and III clinical trials. An internationally recognized leader in HCC, Dr. Zhu has led early efforts of developing several molecularly targeted agents in liver cancer. Dr. Zhu obtained an M.D. degree from Beijing Medical University and a Ph.D. from Columbia university.